Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. Checkpoint inhibitors in breast cancer - Current status

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Prognostic factors in Hodgkin's disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Drugs and diseases: Summary and consensus statements of group 1. The 5th EAO Consensus Conference 2018

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The effect of antiresorptive drugs on implant therapy: Systematic review and meta-analysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. A multicenter case registry study on medication-related osteonecrosis of the jaw in patients with advanced cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Medication-related osteonecrosis of the jaw (MRONJ) is primarily an adverse side effect of denosumab or bisphosphonates (particularly when used at high doses to prevent skeletal-related events [SREs] in patients with cancer and bone metastases) or possibly anti-angiogenic cancer treatment. While the implementation of preventive measures over recent years has reduced the risk of MRONJ in patients with bone metastases due to cancer, it is imperative to balance the risk of MRONJ against the beneficial effects of treatment with denosumab or bisphosphonates on the skeletal health of patients. Despite growing awareness of MRONJ within the medical community, there is a lack of large-scale, prospective clinical studies in this rapidly evolving field. Discussing preventive measures with patients and implementing them, both before and during treatment with bisphosphonates or denosumab, is the best option to reduce the risk of MRONJ. In particular, avoiding bone trauma and preventing and treating dental infections before and during denosumab or bisphosphonate therapy is crucial to minimize the risk of MRONJ. If MRONJ develops, conservative (non-surgical) treatment can provide symptom relief, but achieving mucosal closure remains challenging. When management of symptoms and mucosal healing are the ultimate goals of therapy, or after failure of conservative treatment, a surgical approach may be beneficial. This critical review, based on a best-evidence review of currently available literature, provides clear practical guidelines to help to prevent, manage and treat MRONJ. Overall, a multidisciplinary, pragmatic approach to MRONJ should be adopted, prioritizing patient's quality of life and management of their skeletal malignant disease.

OriginalsprogEngelsk
TidsskriftCancer Treatment Reviews
Vol/bind69
Sider (fra-til)177-187
Antal sider11
ISSN0305-7372
DOI
StatusUdgivet - sep. 2018

ID: 56437468